Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2366770 | 0.99 | PARP1 (0.98) | PARP1 | |
| SCHEMBL2366664 | 0.90 | PARP1 (0.82) | PARP1 | |
| Hydrochloric Acid SCHEMBL2366720 | 0.89 | PARP1 (0.81) | PARP1 | |
| SCHEMBL2366882 | 0.83 | PARP1 (0.71) | PARP1 | |
| Hydrochloric Acid SCHEMBL2367012 | 0.82 | PARP1 (0.69) | PARP1 | |
| SCHEMBL2366355 | 0.82 | PARP1 (0.69) | PARP1 | |
| SCHEMBL2366274 | 0.76 | PARP1 (1.00) | PARP1 | |
| SCHEMBL2366512 | 0.76 | PARP1 (0.60) | PARP1 | |
| Hydrochloric Acid SCHEMBL2366728 | 0.75 | PARP1 (0.98) | PARP1 | |
| Hydrochloric Acid SCHEMBL2366833 | 0.75 | PARP1 (0.59) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815891-B2 | Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2014-08-26 | — | — | US | claimed |
| EP-2364983-B1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JEIL PHARMACEUTICAL CO LTD (KR) | 2013-10-23 | — | — | EP | claimed |
| EP-2364983-A2 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Jeil Pharmaceutical Co., Ltd. (KR) | 2011-09-14 | — | — | EP | claimed |
| US-20110218193-A1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2011-09-08 | — | — | US | claimed |
| US-8815891-B2 | Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2014-08-26 | — | — | US | disclosed |
| US-8815891-B2 | Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2014-08-26 | — | — | US | disclosed |
| US-8815891-B2 | Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2014-08-26 | — | — | US | disclosed |
| EP-2364983-B1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JEIL PHARMACEUTICAL CO LTD (KR) | 2013-10-23 | — | — | EP | disclosed |
| EP-2364983-B1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JEIL PHARMACEUTICAL CO LTD (KR) | 2013-10-23 | — | — | EP | disclosed |
| EP-2364983-A2 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Jeil Pharmaceutical Co., Ltd. (KR) | 2011-09-14 | — | — | EP | disclosed |
| EP-2364983-A2 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Jeil Pharmaceutical Co., Ltd. (KR) | 2011-09-14 | — | — | EP | disclosed |
| US-20110218193-A1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2011-09-08 | — | — | US | disclosed |
| US-20110218193-A1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2011-09-08 | — | — | US | disclosed |
| US-20110218193-A1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218193-A1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | PARP1, PARP15, PARP11 | PARP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.